ELECTREON
9.3.2022 09:02:12 CET | Business Wire | Press release
Electreon intends to enter the Finnish market through a collaboration with Destia, the biggest infrastructure service company and a leading provider of charging infrastructure services in Finland. The companies have signed a Memorandum of Understanding (MoU) and as part of the collaboration, the companies will first showcase the wireless charging solution to potential customers by integrating the Electreon wireless system to a commercial electric vehicle (EV). This will give fleet operators the opportunity to experience the benefits of wireless charging in operation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220309005236/en/
The goal of the collaboration is to develop commercial wireless charging projects, where Electreon’s wireless charging system and related operation and maintenance services could be provided as part of Destia’s Charging as a Service solution. Destia offers EV charging solutions for businesses and professional transport, its customers include bus operators, logistics companies, vehicle manufacturers and taxi companies.
Both companies see great potential for wireless charging and wireless Electric Road System (ERS) projects in Finland for different use cases such as buses, delivery trucks, vans, and taxis. ERS deployments can help decrease greenhouse gas emissions from the transport sector and create conditions for electric vehicle commercialization.
This MoU is part of Electreon’s strategy to accelerate its penetration to the Nordic market which has a huge potential as an early adopter of electric mobility. Maher Kasskawo, an e-mobility specialist from one of the Nordic region’s leading public transport operators, has recently joined Electreon as the Nordics business development manager to head the company’s efforts. Mr. Kasskawo has multiple years of experience of Nordic e-bus and charging systems implementation and operation.
“We are very excited to establish the partnership between Destia and Electreon in the Finnish market. Combining Destia’s strength in charging infrastructure and services with Electreon’s seamless technology in both static and dynamic wireless charging will be a competitive solution for many operational businesses within the transportation segment,” says Maher Kasskawo, Business Development Manager, Electreon.
“Wireless charging has great potential especially in the professional transport segment, because it can be fully integrated into infrastructure with no visual impacts and cables. Electreon’s wireless charging technology can complement our EV Charging as a Service solution nicely,” says Jere Jokinen, Head of EV Charging at Destia.
About Electreon
Electreon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. Electreon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com .
About Destia
Destia is the biggest infrastructure service company in Finland. Our services cover the entire infrastructure life cycle from design to construction and maintenance. We create urban construction innovations and smart infrastructure solutions that facilitate the movement of people, goods, services and energy as part of northern life. We build tomorrow’s infrastructure with the unique sense of infrastructure of more than 1,600 professionals. Destia’s revenue amounted to approximately MEUR 565 in 2020. Destia is part of the international Colas Group.www.destia.fi/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220309005236/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom